SI2206719T1 - Farmacevtski sestavek obsegajoäś 3-beta-hidroksi-17-(1-h-benzimidazol-1-il)androsta-5,16-dien - Google Patents

Farmacevtski sestavek obsegajoäś 3-beta-hidroksi-17-(1-h-benzimidazol-1-il)androsta-5,16-dien

Info

Publication number
SI2206719T1
SI2206719T1 SI200631883T SI200631883T SI2206719T1 SI 2206719 T1 SI2206719 T1 SI 2206719T1 SI 200631883 T SI200631883 T SI 200631883T SI 200631883 T SI200631883 T SI 200631883T SI 2206719 T1 SI2206719 T1 SI 2206719T1
Authority
SI
Slovenia
Prior art keywords
diene
methods
androsta
benzimidazole
beta
Prior art date
Application number
SI200631883T
Other languages
English (en)
Slovenian (sl)
Inventor
Angela Brodie
Vincent Njar
Original Assignee
University Of Maryland, Baltimore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Maryland, Baltimore filed Critical University Of Maryland, Baltimore
Publication of SI2206719T1 publication Critical patent/SI2206719T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200631883T 2005-03-02 2006-03-02 Farmacevtski sestavek obsegajoäś 3-beta-hidroksi-17-(1-h-benzimidazol-1-il)androsta-5,16-dien SI2206719T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65739005P 2005-03-02 2005-03-02
EP10150763.0A EP2206719B1 (en) 2005-03-02 2006-03-02 Pharmaceutical composition comprising 3-beta-hydroxy-17-(1-h-benzimidazole-1-yl)androsta-5,16-diene

Publications (1)

Publication Number Publication Date
SI2206719T1 true SI2206719T1 (sl) 2015-03-31

Family

ID=36941503

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200631883T SI2206719T1 (sl) 2005-03-02 2006-03-02 Farmacevtski sestavek obsegajoäś 3-beta-hidroksi-17-(1-h-benzimidazol-1-il)androsta-5,16-dien
SI200630861T SI1853619T1 (sl) 2005-03-02 2006-03-02 3-beta-hidroksi-17-(1H-benzmidazol-1-il)androsta-5,16-dien za uporabo pri zdravljenju bolezni prostate

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200630861T SI1853619T1 (sl) 2005-03-02 2006-03-02 3-beta-hidroksi-17-(1H-benzmidazol-1-il)androsta-5,16-dien za uporabo pri zdravljenju bolezni prostate

Country Status (21)

Country Link
US (1) US7875599B2 (enExample)
EP (2) EP2206719B1 (enExample)
JP (2) JP5130453B2 (enExample)
KR (1) KR101380959B1 (enExample)
CN (2) CN101155823A (enExample)
AT (1) ATE482969T1 (enExample)
AU (1) AU2006218711B2 (enExample)
BR (1) BRPI0607523A2 (enExample)
CA (1) CA2599953C (enExample)
DE (1) DE602006017175D1 (enExample)
DK (2) DK2206719T3 (enExample)
EA (1) EA019560B1 (enExample)
ES (2) ES2528055T3 (enExample)
IL (3) IL185608A (enExample)
MX (1) MX2007010593A (enExample)
NZ (1) NZ561571A (enExample)
PL (2) PL2206719T3 (enExample)
PT (2) PT1853619E (enExample)
SI (2) SI2206719T1 (enExample)
WO (1) WO2006093993A1 (enExample)
ZA (1) ZA200708106B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
ATE482969T1 (de) * 2005-03-02 2010-10-15 Univ Maryland 3-beta-hydroxy-17-(1h-benzimidazol-1-yl)androst - 5,16-dien zur anwendung in der behandlung von prostata-erkrankungen
GB2454118B (en) 2007-06-06 2010-06-02 Univ Maryland Hdac inhibitors and hormone targeted drugs for the treatment of cancer
GB2470873A (en) * 2008-03-12 2010-12-08 Univ Maryland Androgen receptor inactivation contributes to antitumor efficacy of CYP17 inhibitors in prostrate cancer
US20100048913A1 (en) * 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
GB2470700B (en) * 2008-03-25 2012-08-08 Univ Maryland C-17 heteroaryl steroidal CYP17 inhibitors
US8785423B2 (en) * 2008-04-14 2014-07-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases
US20110190323A1 (en) 2008-08-28 2011-08-04 President And Fellows Of Harvard College Cortistatin analogues and syntheses thereof
CN102282133A (zh) * 2008-10-28 2011-12-14 生物马林药物股份有限公司 十氢-1h-茚并喹啉酮和十氢-3h-环戊并菲啶酮cyp17抑制剂
GB2479337A (en) * 2009-02-05 2011-10-05 Tokai Pharmaceuticals Inc Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent
US8791095B2 (en) 2009-02-05 2014-07-29 Tokai Pharmaceuticals, Inc. Steroidal CYP17 inhibitors/antiandrogens
US20110312916A1 (en) * 2009-02-05 2011-12-22 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
SG176105A1 (en) 2009-06-26 2011-12-29 Novartis Ag 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
US8791094B2 (en) * 2009-08-07 2014-07-29 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer
BR112012012167A2 (pt) * 2009-11-13 2017-10-03 Tokai Pharmaceuticals Inc Metabólitos mamíferos de esteróides
US20110129423A1 (en) * 2009-11-30 2011-06-02 Frincke James M Anticancer compounds and screening method
CN103108871B (zh) 2010-09-16 2014-09-10 诺华股份有限公司 17α-羟化酶/C17,20-裂合酶抑制剂
RU2013132766A (ru) * 2010-12-16 2015-01-27 Байомарин Фармасьютикал Инк. Ингибиторы cyp11b, cyp17 и/или cyp21
US9029399B2 (en) 2011-04-28 2015-05-12 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
JP2014523445A (ja) * 2011-07-18 2014-09-11 トーカイ ファーマシューティカルズ，インク． 前立腺癌を処置するための新規な組成物及び方法
WO2013096907A1 (en) * 2011-12-22 2013-06-27 Tokai Pharmaceuticals, Inc. Methods and compositions for combination therapy using p13k/mtor inhibitors
KR20150127720A (ko) 2013-03-14 2015-11-17 유니버시티 오브 매릴랜드, 발티모어 안드로겐 수용체 하향 조절제 및 그의 용도
EP3514147B1 (en) * 2013-04-04 2022-08-03 University of Maryland, Baltimore Steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity
EP3033088A4 (en) 2013-08-12 2017-03-08 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
AU2014369834B2 (en) 2013-12-24 2018-12-20 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
CN103694299A (zh) * 2014-01-13 2014-04-02 中国药科大学 甾体类雄激素受体抑制剂、其制备方法及其医药用途
CN105732759A (zh) * 2015-01-29 2016-07-06 苏州晶云药物科技有限公司 (3β)-17-(1H-苯并咪唑-1-基)雄甾-5，16-二烯-3-醇的盐及其制备方法
WO2016182932A1 (en) 2015-05-08 2016-11-17 President And Fellows Of Harvard College Cortistatin analogues, syntheses, and uses thereof
EP3316889A4 (en) 2015-07-01 2018-11-14 President and Fellows of Harvard College Cortistatin analogues and syntheses and uses thereof
WO2017066697A1 (en) 2015-10-14 2017-04-20 Dou Qingping Treatments and diagnostics for cancers
IT201600121375A1 (it) * 2016-11-30 2018-05-30 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 3ß-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
RU2749134C1 (ru) * 2016-08-08 2021-06-04 Индустриале Кимика С.Р.Л. СПОСОБ ПОЛУЧЕНИЯ 3β-ГИДРОКСИ-17-(1Н-БЕНЗИМИДАЗОЛ-1-ИЛ)АНДРОСТА-5,16-ДИЕНА
IT201600083406A1 (it) * 2016-08-08 2018-02-08 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 3β-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
CA3087286C (en) 2018-02-13 2023-06-27 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase degraders and methods of use
EP3752518B1 (en) * 2018-02-13 2024-12-04 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase inhibitors and methods of use
WO2021108581A1 (en) 2019-11-26 2021-06-03 Dana-Farber Cancer Institute, Inc. Potent and selective azaindole inhibitors of cdk8 and cdk19

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA27440A (en) 1887-08-16 James T. Walsh Art of making sheet metal cans, for packing meats, fruits, vegetables, etc.
CH621803A5 (enExample) * 1974-08-08 1981-02-27 Siphar Sa
US5604213A (en) * 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5994335A (en) 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
WO2005014023A1 (en) 2003-07-29 2005-02-17 Dompe' Pha.R.Ma S.P.A. Pharmaceutical combination of g-csf and plgf useful for blood stem cell
ATE482969T1 (de) * 2005-03-02 2010-10-15 Univ Maryland 3-beta-hydroxy-17-(1h-benzimidazol-1-yl)androst - 5,16-dien zur anwendung in der behandlung von prostata-erkrankungen

Also Published As

Publication number Publication date
DK1853619T3 (da) 2011-01-10
EA019560B1 (ru) 2014-04-30
EP1853619A1 (en) 2007-11-14
ES2528055T3 (es) 2015-02-03
US7875599B2 (en) 2011-01-25
KR101380959B1 (ko) 2014-04-04
EP2206719A2 (en) 2010-07-14
AU2006218711A1 (en) 2006-09-08
JP2012255026A (ja) 2012-12-27
PL1853619T3 (pl) 2011-03-31
ZA200708106B (en) 2008-12-31
IL185608A0 (en) 2008-01-06
HK1115387A1 (en) 2008-11-28
DE602006017175D1 (de) 2010-11-11
PT2206719E (pt) 2015-02-05
NZ561571A (en) 2009-09-25
BRPI0607523A2 (pt) 2009-09-08
CA2599953A1 (en) 2006-09-08
MX2007010593A (es) 2008-02-20
WO2006093993A1 (en) 2006-09-08
ATE482969T1 (de) 2010-10-15
CN101155823A (zh) 2008-04-02
ES2353413T3 (es) 2011-03-01
AU2006218711B2 (en) 2010-11-11
JP5130453B2 (ja) 2013-01-30
US20080280864A1 (en) 2008-11-13
EP1853619B1 (en) 2010-09-29
CN103349664A (zh) 2013-10-16
IL210478A0 (en) 2011-03-31
CA2599953C (en) 2013-08-13
AU2006218711A2 (en) 2006-09-08
IL210480A (en) 2015-06-30
IL185608A (en) 2016-06-30
DK2206719T3 (en) 2015-01-26
JP2008536807A (ja) 2008-09-11
PT1853619E (pt) 2011-01-03
EP1853619A4 (en) 2009-08-26
JP5613206B2 (ja) 2014-10-22
IL210480A0 (en) 2011-03-31
PL2206719T3 (pl) 2015-03-31
EP2206719A3 (en) 2011-01-05
SI1853619T1 (sl) 2011-01-31
KR20070120119A (ko) 2007-12-21
EP2206719B1 (en) 2014-10-22
EA200701872A1 (ru) 2008-06-30

Similar Documents

Publication Publication Date Title
PL2206719T3 (pl) Kompozycja farmaceutyczna zawierająca 3-beta-hydroksy-17-(1-h-benzimidazol-1-il)androsta-5,16-dien
PT1353672E (pt) Síntese da 4-amino talidomida enantiómeros
EP2966065A3 (en) Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
WO2007087548A3 (en) Chemical compounds
PL1934174T3 (pl) Azetydyny jako inhibitory w leczeniu chorób proliferacyjnych
MX2009003876A (es) Uso de compuestos de espiro-oxindol como agentes terapeuticos.
WO2009120565A3 (en) Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
NO20076319L (no) Farmasoytiske sammensetninger av et neuroaktivt steroid og anvendelse derav
AU2010210422A8 (en) Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
GEP20115213B (en) Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
WO2005077968A8 (en) 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity
WO2005103010A3 (en) Pyrazole derivatives useful for the treatment of cancer
WO2008011539A3 (en) Anesthetic compounds
CY1115910T1 (el) ΦΑΡΜΑΚΕΥΤΙΚΗ ΣΥΝΘΕΣΗ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΕΙ 3-BETA-HYDROXY-17-(l-HBENZIMIDAZOLE-1-YL)ANDROSΤΑ-5,16-DIENE
UA93198C2 (ru) Производные пиразола, способ их получения, их применения, фармацевтическая композиция (варианты) и способ лечения злокачественного новообразования (варианты)
TW200603812A (en) D-homo-17-chlor-16(17)-ene steroids
TW200740442A (en) Therapeutic agent for hypertension
UA96742C2 (en) Mek inhibitors and use thereof